UBS

Ashwani Verma

Q: How accurate are Ashwani Verma's stock ratings?

About 70% of Ashwani's ratings were profitable over a one-year hold, with an average return of +21.1% per rating, measured by 13Foresight from historical prices.

Q: How is Ashwani ranked?

Ashwani Verma is ranked #118 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

UBS

Wall Street Analyst

★★★★★

#118

on 13Foresight · ranked by our own returns

68%

Success Rate

+14.9%

Average Return

34 of 50 calls profitable · +7.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 68% of Ashwani Verma's ratings turned a profit when each position was held for 1 year — averaging +14.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

72 Buy 25 Hold 0 Sell

Ashwani's Stock Coverage 29 ratings · 2026-08-05

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
JAZZ Jazz Pharmaceuticals	Aug 04, 2026	BUY	Strong Buy -9.3% avg upside 35 analysts	$315.00 26.17% Upside	+0.0%	·
AMRX Amneal Pharmaceuticals	Aug 03, 2026	BUY	Strong Buy -4.9% avg upside 18 analysts	$25.00 36.61% Upside	-2.0%	·
NBIX Neurocrine	Jul 31, 2026	BUY	Strong Buy +12.4% avg upside 37 analysts	$231.00 37.98% Upside	+0.0%	·
TEVA Teva Pharmaceutical	Jul 30, 2026	BUY	Buy -12.9% avg upside 39 analysts	$42.00 22.77% Upside	-3.9%	·
CRNX Crinetics Pharmaceuticals	Jul 28, 2026	HOLD	Buy -7.6% avg upside 21 analysts	$85.00 1.26% Upside	-0.1%	·
INCY Incyte	Jul 28, 2026	HOLD	Buy -10.1% avg upside 47 analysts	$113.00 4.91% Downside	-8.0%	·
LEGN Legend Biotech	Jul 24, 2026	HOLD	Strong Buy +236.0% avg upside 27 analysts	$28.00 46.11% Upside	-13.9%	·
MDGL Madrigal Pharmaceuticals	Jul 21, 2026	BUY	Strong Buy -0.0% avg upside 33 analysts	$669.00 33.55% Upside	-7.2%	·
MPLT MapLight Therapeutics, Inc.	Jul 21, 2026	BUY	Strong Buy +174.4% avg upside 13 analysts	$52.00 306.29% Upside	-65.2%	·
VTRS Viatris	Jul 21, 2026	BUY	Buy +31.7% avg upside 21 analysts	$23.00 31.45% Upside	+0.2%	·
EXEL Exelixis	Jul 02, 2026	HOLD	Buy -23.6% avg upside 34 analysts	$52.00 6.88% Downside	+0.8%	·
CYTK Cytokinetics	Jun 29, 2026	BUY	Strong Buy +13.8% avg upside 36 analysts	$115.00 48.81% Upside	-13.9%	·
INSM Insmed	Jun 03, 2026	BUY	Strong Buy +74.5% avg upside 37 analysts	$166.00 67.47% Upside	-4.9%	·
BHVN Biohaven Ltd.	May 28, 2026	HOLD	Buy +67.2% avg upside 25 analysts	$11.00 18.88% Downside	+30.6%	·
CORT Corcept Therapeutics	May 13, 2026	BUY	Buy -46.8% avg upside 15 analysts	$72.00 34.38% Downside	+92.4%	·
ALKS Alkermes	May 06, 2026	BUY	Strong Buy -16.3% avg upside 34 analysts	$48.00 2.88% Downside	+38.7%	·
RPRX Royalty Pharma	Apr 20, 2026	BUY	Strong Buy -2.6% avg upside 15 analysts	$57.00 1.36% Downside	+17.1%	·
AXSM Axsome Therapeutics	Apr 10, 2026	BUY	Strong Buy +9.5% avg upside 29 analysts	$259.00 22.49% Upside	+22.4%	·
ALVO Alvotech	Mar 24, 2026	BUY	Buy +108.6% avg upside 6 analysts	$6.00 55.92% Upside	+23.6%	·
UTHR United Therapeutics	Mar 05, 2026	BUY	Buy -16.2% avg upside 26 analysts	$705.00 36.55% Upside	+7.7%	·
ACAD ACADIA Pharmaceuticals	Jan 05, 2026	BUY	Strong Buy +35.8% avg upside 43 analysts	$40.00 54.88% Upside	+3.8%	·
ABBV AbbVie	Nov 07, 2025	HOLD	Strong Buy -2.5% avg upside 46 analysts	$220.00 9.80% Downside	+14.7%	·
LLY Eli Lilly & Co	Nov 07, 2025	BUY	Strong Buy -7.4% avg upside 48 analysts	$1080.00 4.00% Downside	+24.9%	·
HRMY Harmony Biosciences Holdings	Oct 14, 2025	BUY	Strong Buy +25.5% avg upside 13 analysts	$43.00 10.65% Upside	+33.6%	·
IMVT Immunovant	Jul 29, 2025	HOLD	Strong Buy -0.5% avg upside 24 analysts	$18.00 54.20% Downside	+131.9%	·
CHRS Coherus Biosciences	Jul 21, 2025	HOLD	Buy +749.8% avg upside 18 analysts	$1.10 25.58% Downside	+65.2%	·
BIIB Biogen	Jul 14, 2025	HOLD	Strong Buy +22.1% avg upside 52 analysts	$130.00 36.34% Downside	+44.2%	·
RCKT Rocket Pharmaceuticals	Jun 17, 2025	BUY	Buy +379.8% avg upside 29 analysts	$5.00 46.17% Upside	+16.2%	·
RANI Rani Therapeutics Holdings	Oct 11, 2022	BUY	Strong Buy +1056.5% avg upside 10 analysts	$15.00 1664.86% Upside	-75.5%	·

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Ashwani Verma — Frequently Asked Questions

How accurate are Ashwani Verma's stock ratings?

Based on the calls 13Foresight could measure, about 70% of Ashwani's ratings were profitable over a one-year hold, with an average return of +21.1% per rating, or +15.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Ashwani ranked on 13Foresight?

Ashwani Verma is currently ranked #118 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Ashwani cover?

Ashwani most recently has ratings on JAZZ, AMRX, NBIX, TEVA, CRNX, INCY, LEGN, MDGL, MPLT, VTRS, EXEL, CYTK and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Ashwani Verma

Rating Distribution

Welcome to 13Foresight!